Bioactive and total TGF-β1 content in the plasma of PMF patients and nondiseased controls and in that of wild-type and Gata1low mice
| Specimen . | Bioactive TGF-β1, ng/mL* . | Total TGF-β1, ng/mL . |
|---|---|---|
| Human plasma | ||
| Nondiseased controls (n = 29) | 18 (0.05-144) | 52 (8-860) |
| PMF patients All (n = 64, 52 plus 6 of unknown JAK2V617F status) | 43 (4-218) | 153 (32-1000) |
| P = .014 | P = .005 | |
| JAK2V617F negative (n = 24) | 44 (8-136) | 130 (25-400) |
| JAK2V617F heterozygous (n = 20) | 44 (4-200) | 135 (30-500) |
| JAK2V617F homozygous (n = 14) | 26.2 (15-112) | 200 (100-1000) (P = .03 and .05 with respect to JAK2V617F heterozygous or negative) |
| Murine plasma | ||
| Wild type | 1.5 (0.01-8.2) (n = 12) | 10.5 (2.5-23) (n = 9) |
| Gata1low | 2.4 (0.01-8.2) P < .01 (n = 20) | 17.7 (8.5-39) P < .01 (n = 20) |
| Specimen . | Bioactive TGF-β1, ng/mL* . | Total TGF-β1, ng/mL . |
|---|---|---|
| Human plasma | ||
| Nondiseased controls (n = 29) | 18 (0.05-144) | 52 (8-860) |
| PMF patients All (n = 64, 52 plus 6 of unknown JAK2V617F status) | 43 (4-218) | 153 (32-1000) |
| P = .014 | P = .005 | |
| JAK2V617F negative (n = 24) | 44 (8-136) | 130 (25-400) |
| JAK2V617F heterozygous (n = 20) | 44 (4-200) | 135 (30-500) |
| JAK2V617F homozygous (n = 14) | 26.2 (15-112) | 200 (100-1000) (P = .03 and .05 with respect to JAK2V617F heterozygous or negative) |
| Murine plasma | ||
| Wild type | 1.5 (0.01-8.2) (n = 12) | 10.5 (2.5-23) (n = 9) |
| Gata1low | 2.4 (0.01-8.2) P < .01 (n = 20) | 17.7 (8.5-39) P < .01 (n = 20) |
Values observed in PMF patients according to JAK2V617F state are also reported.
Values are expressed as median (min-max) determinations.